Britain and America have reached a landmark trade agreement that will guarantee no tariffs on British drug exports being sold in the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to increase spending on medicines through the NHS. This move ensures that duties on these key exports will stay at nothing for a duration of the next three years.
This deal comes after previous warnings to significantly raise import taxes on patented pharmaceutical products, with increases discussed up to 100%.
"This agreement between the Britain reinforces the worldwide climate for cutting-edge drugs and establishes long-overdue equity to U.S.–U.K. drug exports," an announcement declared.
Commercial Impact
Medicines represent one of the UK's largest exports to the United States, which is clearly the biggest destination for major companies like GSK and AstraZeneca.
Statistics reveal that in the one-year period leading up to September, the UK shipped pharmaceutical products worth billions to the US. This amount represented 17.4% of British export trade in that span.
"This deal protects work, increases capital expenditure and facilitates the UK to become a global hub for life sciences," the Business and Trade Secretary stated.
Specific NHS Changes
The pact involves several notable commitments from the UK:
- Revised Affordability Limit: The UK will raise the affordability limit at which it deems new treatments to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to increase total NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must return to the NHS to stay within budget will be limited at fifteen percent. In the past, refunds were more than twenty percent.
Recent Tensions
The deal follows a long-running tension between the drug companies and the UK government over medicine costs and approval rates.
These tensions were intensified by assertions that American customers were charged a premium for the equivalent treatments than people in the other developed nations.
Recently, several major drug company projects in the UK have been halted or scrapped, while multi-billion-dollar investments have been announced toward projects in the United States.
A senior figure acknowledged that the NHS had to invest a greater share on drugs, noting that its spending on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
